Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00020124 · ClinicalTrials.gov registry record · Phase 1

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
Phase 1
Development phase

NCT00020124: Completed Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).

NCT00020124 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00020124, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have advanced solid tumors affecting the lungs.

Interventions

  • DRUG doxorubicin hydrochloride

Trial Details

FieldValue
Start Date 2000-06
Est. Completion 2002-12
Phase Phase 1

What the finished NCT00020124 record still lists

NCT00020124 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which doxorubicin hydrochloride is the first listed.

NCT00020124 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00020124 about?

NCT00020124 is a clinical study titled "Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have advanced solid tum...

What is the current status of trial NCT00020124?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-06. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00020124?

The interventions under investigation include: doxorubicin hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00020124?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00020124, the US trial registry maintained by the National Library of Medicine. NCT00020124 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.